Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep. 01, 2022 4:19 PM ETIntellia Therapeutics, Inc. (NTLA)By: Anuron Mitra, SA News Editor2 Comments

alphabet letters spelling angioedema

Sopone Nawoot

  • Intellia Therapeutics (NASDAQ:NTLA) on Thursday said the U.S. FDA had granted an orphan drug designation to the company's genome editing candidate NTLA-2002 for the treatment of hereditary angioedema (HAE), a disorder characterized by recurring episodes of severe swelling.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.